z-logo
open-access-imgOpen Access
In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1
Author(s) -
Usman Sumo Friend Tambunan,
Rizky Arcinthya Rachmania,
Arli Aditya Parikesit
Publication year - 2015
Publication title -
journal of biomedical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.617
H-Index - 31
eISSN - 2352-4685
pISSN - 1674-8301
DOI - 10.7555/jbr.29.20130024
Subject(s) - oseltamivir , neuraminidase , in silico , chemistry , neuraminidase inhibitor , influenza a virus , docking (animal) , hydrogen bond , virology , molecular dynamics , virus , biology , enzyme , biochemistry , medicine , molecule , gene , organic chemistry , computational chemistry , pathology , covid-19 , infectious disease (medical specialty) , nursing , disease
This research focused on the modification of the functional groups of oseltamivir as neuraminidase inhibitor against influenza A virus subtype H1N1. Interactions of three of the best ligands were evaluated in the hydrated state using molecular dynamics simulation at two different temperatures. The docking result showed that AD3BF2D ligand (N-[(1S,6R)-5-amino-5-{[(2R,3S,4S)-3,4-dihydroxy-4-(hydroxymethyl) tetrahydrofuran-2-yl]oxy}-4-formylcyclohex-3-en-1-yl]acetamide-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate) had better binding energy values than standard oseltamivir. AD3BF2D had several interactions, including hydrogen bonds, with the residues in the catalytic site of neuraminidase as identified by molecular dynamics simulation. The results showed that AD3BF2D ligand can be used as a good candidate for neuraminidase inhibitor to cope with influenza A virus subtype H1N1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom